Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO - 204)

Trial Profile

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO - 204)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epacadostat (Primary) ; Nivolumab (Primary)
  • Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Diffuse large B cell lymphoma; Glioblastoma; Head and neck cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ECHO-204
  • Sponsors Bristol-Myers Squibb; Incyte Corporation
  • Most Recent Events

    • 09 Jul 2019 Planned End Date changed from 1 Oct 2020 to 18 Jul 2020.
    • 05 Jun 2018 Results (Data cut off: 29 Oct, 2017; n=50) from expansion cohort of the study presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 10 May 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top